English 
Central Precocious Puberty | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00
Description
Central precocious puberty (CPP) Epidemiology
CPP has an incidence of 1 in 5-10,000 children with a female to male ratio of about 20:1 although this ratio is debated. Eighty to ninety percent of girls with true PP (precocious puberty) have idiopathic CPP whereas over 50% of boys have an identifiable etiology for true PP. In 2020, the estimated CPP cases in US are the highest followed by European 5 countries (Germany, France, Italy, Spain & UK) and Japan.
Total treated cases of CPP will also rise from ~8000 cases in 2019 to xxx in 2030 in the G7 countries due to the rising awareness of the disease, expected launch and expanded use of the long-acting potential therapies, which will shift the market from short term treatments to the effective long-term treatments.
As per multiple studies, Idiopathic CPP are the most common form of CPP. The environmental pollutants, especially the pesticides have been known to behave as estrogen-like and androgens antagonist. These pollutants act as endocrine disruptors and have estrogenic, antiestrogenic, androgenic, and antiandrogenic effect on puberty and directly on the GnRH system.
Central precocious puberty (CPP) Market Forecast
The Central Precocious Puberty (CPP) therapy market is expected to experience moderate growth throughout our study period, increasing from $xxx million in 2019 to $xxx million in 2032, representing 5.43% annual growth. Primary drivers of this growth will be uptake of the novel 6 months treatment i.e., Triptorelin 6-month Formulation (Arbor’s Triptodur) and the Leuprolide Acetate (LA) 6-month Formulation (Tolmar’s Fensolvi), along with an expanding number of diagnosed and treated CPP cases, predominantly in the United States.
The Leuprolide Acetate (AbbVie’s Lupron) accounts for the larger segment of the drug-treated CPP population share. In 2019, sales of Leuprolide Acetate therapies accounted for approximately 65% of major-market CPP sales because of the physician’s preference over the surgical treatments. In addition, patients also undergo surgical treatment with Histrelin Subcutaneous Implant (Endo’s Supprelin LA) , which accounts for 31% of the total market share in 2022. The long-term use of Leuprolide Acetate, newer 6 months formulation therapies —and, to a lesser extent, generic and Synarel, Zoladex and other therapies—will drive sales of CPP market from $xxx million in 2022 to $xxx million in 2032.
Report Highlights
- Central Precocious Puberty (CPP) Current Market Trends
- Central Precocious Puberty (CPP) Current & Forecasted Cases across the G7 Countries
- Central Precocious Puberty (CPP) Market Opportunities And Sales Potential for Agents
- Central Precocious Puberty (CPP) Patient-based Market Forecast to 2032
- Central Precocious Puberty (CPP) Untapped Business Opportunities
- Central Precocious Puberty (CPP) Product Positioning Vis-a-vis Competitors’ Products
- Central Precocious Puberty (CPP) KOLs Insight
Additional information
| Price | 2-3 User License, Enterprise License, Single User License, Site License |
|---|
Table of Contents
- Central Precocious Puberty Disease Background
- Central Precocious Puberty Definition
- Symptoms
- Risk Factor
- Diagnosis
- Epidemiology Estimated and Forecast to 2032
- Epidemiology Research Method & Data Sources Used
- Incident Cases of Central Precocious Puberty in the United States 2022-2032
- Diagnosed & Treated Cases of Central Precocious Puberty in the United States 2022-2032
- Incident Cases of Central Precocious Puberty in Germany 2022-2032
- Diagnosed & Treated Cases of Central Precocious Puberty in Germany 2022-2032
- Incident Cases of Central Precocious Puberty in France 2022-2032
- Diagnosed & Treated Cases of Central Precocious Puberty in France 2022-2032
- Incident Cases of Central Precocious Puberty in Italy 2022-2032
- Diagnosed & Treated Cases of Central Precocious Puberty in Italy 2022-2032
- Incident Cases of Central Precocious Puberty in Spain 2022-2032
- Diagnosed & Treated Cases of Central Precocious Puberty in Spain 2022-2032
- Epidemiology Research Method & Data Sources Used
-
-
- Incident of Central Precocious Puberty in the United Kingdom 2022-2032
- Diagnosed & Treated Cases of Central Precocious Puberty in the United Kingdom 2022-2032
- Incident Cases of Central Precocious Puberty in Japan 2022-2032
- Diagnosed & Treated Cases of Central Precocious Puberty in Japan 2022-2032
-
- Current Unmet Needs in Central Precocious Puberty
- Current Treatment Paradigm
- Treatment guidelines for Central Precocious Puberty
- Current Therapies Chapters
- Leuprolide Acetate (LA) –AbbVie
- Histrelin Subcutaneous Implant –Endo Pharmaceuticals
- Triptodur –Arbor Pharmaceuticals/Debiopharm International SA
- Fensolvi –Tolmar Pharmaceuticals
- Emerging Therapies Chapters
- Leuprolide Acetate (LA)-6months Formulation –AbbVie
- CPP Product Positioning
- Key Competitors
- Matrix Modeling
- KOLs Insight (US, EU, JP)
- Unmet Needs
- Analysis of the progresses in terms of approvals;
- Impact on the treatment algorithm and product positioning
- Relevance of Therapy Uptake Share %
- Physicians Preferences for the new pharmacological agents
- Total Market Forecast
- Key Summary Findings
- G7 total Market for Central Precocious Puberty 2022-2032 (USD Million)
- G7 total Market for Central Precocious Puberty by Therapies 2022-2032 (USD Million)
- Key Summary Findings
- Market Forecast by Country
- United States
- United States Market for Central Precocious Puberty 2022-2032 (USD Million)
- United States Market for Central Precocious Puberty by Therapies 2022-2032 (USD Million)
- Germany
- Germany Market for Central Precocious Puberty 2022-2032 (USD Million)
- Germany Market for Central Precocious Puberty by Therapies 2022-2032 (USD Million)
- France
- France Market for Central Precocious Puberty 2022-2032 (USD Million)
- France Market for Central Precocious Puberty by Therapies 2022-2032 (USD Million)
- Italy
- Italy Market for Central Precocious Puberty 2022-2032 (USD Million)
- Italy Market for Central Precocious Puberty by Therapies 2022-2032 (USD Million)
- Spain
- Spain Market for Central Precocious Puberty 2022-2032 (USD Million)
- Spain Market for Central Precocious Puberty by Therapies 2022-2032 (USD Million)
- United Kingdom
- United Kingdom Market for Central Precocious Puberty 2022-2032 (USD Million)
- United Kingdom Market for Central Precocious Puberty by Therapies 2022-2032 (USD Million)
- Japan
- Japan Market for Central Precocious Puberty 2022-2032 (USD Million)
- Japan Market for Central Precocious Puberty by Therapies 2022-2032 (USD Million)
- United States
- Market Drivers & Barriers
- Appendix
- About Mellalta Meets
Sample Enquiry
Related products
-
ER+/HER2- Metastatic Breast Cancer (mBC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe ER + / HER2- metastatic breast cancer (mBC) market is relatively large with the highest market share holding CDK4 / 6 drugs, e.g. Pfizer’s Ibrance (palbociclib), Novartis’s Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib). By 2032, these drugs will continue to hold the largest share of the market, but we also expect the market to expand with the addition of new oral SERDs/SARMs/SERMs that will take a combined share of 19.1%, antibody drug conjugates with a share of the 2.9% and AKT inhibitors with a 2.6% share. The sales of the emerging therapies for the treatment of ER+/HER2- mBC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2022-2032 study period, adding a value estimated at a total market of $ 5.6 billion by 2032.
-
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCorticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.
-
Complex regional pain syndrome (CRPS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsComplex regional pain syndrome (CRPS) is a chronic pain condition characterized by spontaneous and evoked regional pain, usually starting in a distal extremity, which is disproportionate in magnitude or duration to the typical pain course after similar tissue trauma. Current treatment for CRPS requires a multidisciplinary approach involving patient education, physical and occupational therapy, psychiatry and pain medicine specialists, along with pharmacological and surgical interventions. Unfortunately, the current available treatment options are generally considered to be ineffective and one-dimensional, as they only treat part of the disease. Emerging therapies like Soticlestat (Takeda / Ovid Therapeutics and Lanicemine (AstraZeneca / Biohaven Pharmaceuticals) is expected to generate more market share than other emerging therapies and have the potential to overcome the treatment barrier.
-
Peripheral T-cell lymphoma (PTCL)| Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsMellalta’s analysts estimate that the United States market is expected to show rapid growth, mainly attributed to, the launch of Adcetris in the front-line setting and expected approval of the potential therapies in the pipeline during the forecast period (2021-2030). Through this, the market size is set to show an extensive jump and grow at a CAGR of 15.3%